New hope for hepatitis b: experimental combo aims to silence the virus

NCT ID NCT05612581

Completed Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The study is part of a larger effort to find better treatments for this long-term liver infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tobevibart (VIR-3434) and Elebsiran (VIR-2218) injections, plus standard oral tenofovir and peginterferon
What this could lead to: If successful, this could point toward a more effective combination therapy to control chronic hepatitis B and reduce the need for lifelong medication.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply broadly. The treatments may not achieve lasting virus suppression or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

Investigative Site

Clichy, 92110, France
Investigative Site

Nice, 06200, France
Investigative Site

Rennes, 35000, France
Investigative Site

Toulouse, 31000, France
Investigative Site

Hong Kong, Sha Tin, Hong Kong
Investigative Site

Hong Kong, Hong Kong
Investigative Site

Chisinau, MD 2025, Moldova
Investigative Site

Bucharest, 021105, Romania
Investigative Site

Busan, 49241, South Korea
Investigative Site

Seoul, 5505, South Korea
Investigative Site

Yangsan, 50612, South Korea
Investigative Site

Glasgow, G4 0SF, United Kingdom
Investigative Site

London, EC1A 7BE, United Kingdom
Investigative Site

London, SE5 9RS, United Kingdom
Investigative Site

Manchester, M8 5RB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.